美罗培南联合磷霉素对肺炎克雷伯菌的药效学组合折点研究
本研究基于12株多重耐药肺炎克雷伯菌的体外动态感染模型数据,采用药效学建模分析美罗培南与磷霉素联合的抗菌效应及药效学相互作用,并模拟九种给药方案计算目标 attainment 概率。结果显示联合治疗产生稳健协同作用,相比单药可扩展可达临床折点,为重新引入磷霉素联合美罗培南折点及后续临床验证提供依据。
要点
- 美罗培南与磷霉素单药仅对低MIC(≤4 mg/L)达到PTA≥90%。
- 低剂量联合(美罗培南2g+磷霉素2g q8h)对抑菌PTA≥90%的MIC可达美罗培南32 mg/L、磷霉素512 mg/L。
- 高剂量联合(美罗培南2g+磷霉素8g q8h)对1-log和2-log killing的PTA≥90%可达更高MIC。
核心结论
- 美罗培南-磷霉素联合对多重耐药肺炎克雷伯菌产生稳健协同作用,相比单药扩展了可达临床折点。
- 研究结果为重新引入磷霉素联合美罗培南的折点提供证据,并支持在重症感染患者中进一步临床验证所提给药方案。
研究设计与样本
- 基于12株临床肺炎克雷伯菌(携带KPC、NDM、OXA-48、VIM、CTX-M、SHV等基因)的体外动态感染模型数据。
- 采用药效学建模,构建以MIC为协变量的非线性混合效应模型。
- 利用已发表群体药代动力学模型模拟九种单药和联合给药方案,计算抑菌、1-log和2-log killing的PTA。
主要发现
- 美罗培南和磷霉素单药仅对低MIC(美罗培南≤4 mg/L,磷霉素≤4 mg/L)达到PTA≥90%。
- 低剂量联合(美罗培南2 g + 磷霉素2 g每8小时)对抑菌PTA≥90%的MIC可达美罗培南32 mg/L和磷霉素512 mg/L,对1-log killing可达32 mg/L和256 mg/L。
- 高剂量联合(美罗培南2 g + 磷霉素8 g每8小时)对1-log和2-log killing的PTA≥90%可达更高MIC。
- 模型共捕捉全部12株菌和9种给药方案的时间-杀菌动态。
关键数值与推荐
- 单药PTA≥90%仅见于美罗培南MIC≤4 mg/L和磷霉素MIC≤4 mg/L。
- 低剂量联合抑菌PTA≥90%:美罗培南MIC≤32 mg/L且磷霉素MIC≤512 mg/L。
- 低剂量联合1-log killing PTA≥90%:美罗培南MIC≤32 mg/L且磷霉素MIC≤256 mg/L。
临床怎么用
- 对多重耐药肺炎克雷伯菌感染,可考虑美罗培南联合磷霉素以提高对较高MIC菌株的达标概率。
- 低剂量联合方案(美罗培南2 g + 磷霉素2 g每8小时)即可扩展抑菌和1-log killing的MIC覆盖范围。
- 高剂量联合方案(美罗培南2 g + 磷霉素8 g每8小时)可进一步覆盖更高MIC的1-log和2-log killing。
- 所提给药方案尚需在重症感染患者中进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To quantify the antibacterial effects and pharmacodynamic interactions of meropenem and fosfomycin combinations against multidrug-resistant Klebsiella pneumoniae through pharmacometric analysis, and to support an evidence-based rationale for combined clinical breakpoints. METHODS: In vitro data from 12 clinical K. pneumoniae strains (carrying genes such as KPC, NDM, OXA-48, VIM, CTX-M, SHV, etc.), generated in dynamic in vitro infection model experiments mimicking human pharmacokinetics of meropenem and fosfomycin, were analysed using pharmacodynamic modelling. A nonlinear mixed-effects model, incorporating MICs as covariates, was developed. Simulations using published population pharmacokinetic models evaluated nine mono and combination dosing regimens (intravenous [i.v.] meropenem 2 g every 8 hours; i.v. fosfomycin 6-24 g total daily dose every 6 hours, every 8 hours, or continuous infusion) and calculated probability of target attainment (PTA) (for bacteriostasis, 1-log, and 2-log killing after 24 hours) for each dosing regimen across wide meropenem and fosfomycin MICs. RESULTS: Meropenem and fosfomycin monotherapies achieved PTA ≥90% only for low MICs (≤4 mg/L for meropenem, ≤4 mg/L for fosfomycin). In contrast, combination therapy enabled PTA ≥90% for bacteriostasis at MICs up to 32 mg/L (meropenem) and 512 mg/L (fosfomycin), and for 1-log killing at 32 mg/L and 256 mg/L, using low-dose regimens (meropenem 2 g + fosfomycin 2 g every 8 hours). For high-dose combinations (meropenem 2 g + fosfomycin 8 g every 8 hours), PTA ≥90% was achieved for 1-log and 2-log killing at even higher MICs. In total, the model captured time-kill dynamics for all 12 strains and 9 distinct drug regimens. CONCLUSIONS: This study demonstrates that meropenem-fosfomycin combination therapy produces robust synergy against multidrug-resistant K. pneumoniae strains, and expands attainable clinical breakpoints compared with monotherapy. These findings provide evidence for reintroducing a fosfomycin breakpoint in combination with meropenem and support further clinical validation of the proposed dosing regimens in patients with severe infections.
引用
- Farooq A, Martens M, Attwood MLG, et al. Meropenem and fosfomycin against Klebsiella pneumoniae: Towards a combination breakpoint using a pharmacometric approach. Clin Microbiol Infect. 2026. PMID: 41796959. doi:10.1016/j.cmi.2026.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。